首页> 外文期刊>Applied Microbiology and Biotechnology >Identification of novel bacteriophage vB_EcoP-EG1 with lytic activity against planktonic and biofilm forms of uropathogenic Escherichia coli
【24h】

Identification of novel bacteriophage vB_EcoP-EG1 with lytic activity against planktonic and biofilm forms of uropathogenic Escherichia coli

机译:鉴定具有裂解性和生物膜形式的裂解性大肠杆菌的血红蛋白和生物膜形式的新型噬菌体VB_ecop-EG1

获取原文
获取原文并翻译 | 示例
           

摘要

Urinary tract infections are one of the most common infectious diseases worldwide. Uropathogenic Escherichia coli (UPEC) is a major cause of unary tract infection. Due to increasing prevalence of multidrug resistance, alternative methods to eradicate the UPECs are urgently needed. In this respect, phage therapy has been demonstrated to be a good candidate. Here, we described a novel bacteriophage named vB_EcoP-EG1, which can infect several strains of UPEC. Phage morphology and genome sequencing analysis show that vB_EcoP-EG1 belongs to the T7-like Podoviridae. vB_EcoP-EG1 possesses a genome (39,919bp) containing 51 predicted genes and 149bp terminal repeats. vB_EcoP-EG1 genome does not encode toxic proteins or proteins related to lysogeny. And no known virulent proteins were found in purified phage particles by mass spectrometry. vB_EcoP-EG1 appeared to be relatively specific and sensitive to clinical UPEC strains, which could infect 10 out of 21 clinical multidrug-resistant UPEC strains. In addition, vB_EcoP-EG1 suspension can eliminate biofilm formed by E. coli MG1655 and multidrug-resistant UPEC strain 390G7. Therefore, we concluded that vB_EcoP-EG1 has desirable characteristics for potential therapy, which may serve as an alternative to antibiotic therapy against urinary tract infections caused by multidrug-resistant UPEC.
机译:尿路感染是全球最常见的传染病之一。尿养性大肠杆菌(UPEC)是一部分是一元感染的主要原因。由于多药耐抗性的普遍性增加,迫切需要迫切需要消除UPEC的方法。在这方面,已证明噬菌体疗法是​​一个好候选者。在这里,我们描述了一个名为VB_ecop-EG1的新型噬菌体,其可以感染若干UPEC菌株。噬菌体形态和基因组测序分析表明,VB_ECOP-EG1属于T7样Povoviridae。 VB_ECOP-EG1具有含有51个预测基因和149bp末端重复的基因组(39,919bp)。 VB_ECOP-EG1基因组不会编码与溶酶体有关的毒性蛋白质或蛋白质。并且在纯化噬菌体颗粒中没有发现已知的毒性蛋白质通过质谱法。 VB_ECOP-EG1似乎对临床UPEC菌株相对特异并且敏感,这可能感染10个临床多药抗性UPEC菌株中的10个。此外,VB_ECOP-EG1悬浮液可以消除由大肠杆菌MG1655和多药抗性UPEC菌株390G7形成的生物膜。因此,我们得出结论,Vb_ecop-eg1具有潜在治疗的理想特征,其可以作为抗生素治疗的替代抗生素治疗由多药抗性UPEC引起的尿路感染。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号